Therapy matched to oncogenic drivers improves survival in metastatic lung adenocarcionoma

Results from the Lung Cancer Mutation Consortium presented at the Presidential Symposium of the 15th World Conference on Lung Cancer (27-30 October 2013, Sydney, Australia) show that patients with lung adenocarcinoma with oncogenic drivers receiving a corresponding targeted agent, lived longer than similar patients who did not. An actionable driver was detected in 64% of tumours from patients with lung adenocarcinomas and more than one was present in 3%. Multiplexed testing aided physicians in choosing therapies and targeted trials in 28% of patients. Read more here.